Trubion Pharmaceuticals

Trubion Pharmaceuticals is a biopharmaceutical company focused on the discovery, development and commercialization of novel medicines to treat inflammatory disease and cancer. The company utilizes proprietary technology to develop drugs that are safer and more effective than currently available therapies. Trubion has developed a proprietary product engine to create a novel class of compounds known as SMIPs™ (Small Modular ImmunoPharmaceuticals). SMIPs are highly-specific, single-chain polypeptides designed with optimized target binding and effector functions to overcome limitations of therapeutic antibodies and antibody alternatives. SMIPs are significantly smaller than antibodies and can reach sites unavailable to larger molecules. These novel compounds can be expressed in mammalian cells and customized for many disease targets.

Contact Details: 2401 4th Ave. Suite 1050 Seattle WA 98121 United States of America Tel: 206-838-0500 Fax: 206-838-0503 Email: hr@trubion.com WWW: www.trubion.com/

Loading...

Recent Publications by Trubion Pharmaceuticals:
CD20-directed small modular immunopharmaceutical, TRU-015, depletes normal and malignant B cells. PURPOSE: CD20-directed therapy with rituximab is effective in many...	6th June, 2009	Trubion Pharmaceuticals, Inc., Seattle, Washington 98121, USA.	Clin Cancer Res. 2009 Apr 15;15(8):2739-46. Epub 2009 Apr 7. DOI Direct Link
Pharmacokinetic and pharmacodynamic properties of TRU-015, a CD20-directed small modular immunopharmaceutical protein therapeutic, in patients with rheumatoid arthritis: a Phase I, open-label, dose-escalation clinical study. BACKGROUND: TRU-015 is a small modular immunopharmaceutical protein drug...	10th February, 2009	Trubion Pharmaceuticals Inc., Seattle, Washington, USA.	Clin Ther. 2008 Oct;30(10):1806-16. DOI Direct Link

Press Releases on Trubion Pharmaceuticals:
Trubion Pharmaceuticals, Inc. Announces Transition in Company Leadership	16th November, 2009	Trubion Pharmaceuticals, Inc.	SEATTLE, Nov. 16 /PRNewswire-FirstCall/ -- Trubion Pharmaceuticals, Inc. (Nasdaq: TRBN) announced today that Peter Thompson, M.D., FACP, President, Chief Executive Officer, Chairman of the Board of
Trubion Announces Acceptance of Two Presentations on Its TRU-016 Product Candidate at the 2009 ASH Annual Meeting	11th November, 2009	Trubion Pharmaceuticals, Inc.	SEATTLE, Nov. 11 /PRNewswire-FirstCall/ -- Trubion Pharmaceuticals, Inc. (Nasdaq: TRBN) announced today the acceptance of two data presentations on its product candidate, TRU-016, at the 2009 American
Trubion Pharmaceuticals, Inc. Reports Third Quarter and Nine Months 2009 Financial Results	5th November, 2009	Trubion Pharmaceuticals, Inc.	-- In Sept. 2009, patient enrollment was completed in the second Phase 2b study (2203) of TRU-015 for RA. 2009 Financial Guidance The company has revised its 2009 guidance after taking
Trubion Announces Dates for Third Quarter and Nine Months 2009 Earnings Conference Call	29th October, 2009	Trubion Pharmaceuticals, Inc.	SEATTLE, Oct. 29 /PRNewswire-FirstCall/ -- Trubion Pharmaceuticals, Inc. (Nasdaq: TRBN), today announced that it plans to issue earnings results for its third quarter and nine months ended Sept. 30,
Trubion Announces Upcoming Presentation at 8th Annual BIO Investor Forum	26th October, 2009	Trubion Pharmaceuticals, Inc.	SEATTLE, Oct. 26 /PRNewswire-FirstCall/ -- Trubion Pharmaceuticals, Inc. (Nasdaq: TRBN), today announced it will present a corporate update at the upcoming 8th Annual BIO Investor Forum to be held at

BioNews Results for Trubion Pharmaceuticals:
Trubion Pharmaceuticals, Inc. Announces Transition in Company Leadership	Pharma Live:  Nov 22 2009 3:01PM Matching: trubion pharmaceuticals
The Icos Alumni Guide, Trubion CEO Resigns, OVP Leads $30M Fate Deal, & More Seattle-Area Life Sciences News	Seattle Post Intelligencer:  Nov 20 2009 7:13AM Matching: trubion pharmaceuticals
The Icos Alumni Guide, Trubion CEO Resigns, OVP Leads $30M Fate Deal, & More Seattle-Area Life Sciences News	Xconomy:  Nov 19 2009 7:14AM Matching: trubion pharmaceuticals
Facet Biotech Announces Four Presentations at American Society of Hematology Annual Meeting	Street Insider:  Nov 19 2009 1:58PM Matching: trubion pharmaceuticals
Facet Biotech Announces Four Presentations at American Society of	Market Wire via MSN Money:  Nov 19 2009 1:49PM Matching: trubion pharmaceuticals
Promote your company here: BioNewsCast - Press Release Distribution	→View more Trubion Pharmaceuticals news.

Trubion Pharmaceuticals Clinical Trials:
A Phase 1/2 Study of TRU-016 in Patients With Previously Treated Chronic Lymphocytic Leukemia

Trubion Pharmaceuticals (TRBN) Financial information Links from Barchart
TRBN Quote from from Barchart.com
TRBN Chart from from Barchart.com
TRBN Profile from from Barchart.com
TRBN Opinion from from Barchart.com
→View more Trubion Pharmaceuticals finance information.

Contact BioPortfolio for a quote for a customised Excel verision of BioCorporate or BioEmail databases.

This page has been viewed 473 times since April 2007, the link to the organisation's website has been followed 81 times

Recent Search Terms used to find this page: trubion hr | trubion human resources | .

Search for more companies in Seattle

Search for more companies in WA

This site uses Thumbshots previews, resources from the NCBI applied. Maps are centred on zip/postcodes and should not be relied upon for exact building locations. Some information on this page has been collected automatically and may not have been verified.
BioPortfolio search results for Trubion Pharmaceuticals